AwardedGermanyGoodsFramework agreement
Vereinbarung nach § 130c SGB V für das Arzneimittel Maviret mit der Wirkstoffkombination Glecaprevir/Pibrentasvir
- Published
- Published 16 July 2026
Overview
AOK PLUS has concluded a pharmaceutical pricing agreement under German social security law (§ 130c SGB V) for the antiviral drug Maviret (active ingredients: glecaprevir/pibrentasvir). AbbVie Deutschland GmbH & Co. KG was awarded the agreement on 7 July 2026.
Key details
- Country
- Germany
- Status
- Awarded
- Category
- Goods
- Procedure
- Direct
- Contract type
- Framework agreement
- Published
- 16 July 2026
Pharmaceutical products
Award outcome
- Award date
- 7 July 2026
- Contract period
- 1 September 2026 → 31 August 2028
- AbbVie Deutschland GmbH & Co. KG
Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.
Notice history
Every published notice in this contracting process, newest first.
Contract Award Notice
16 July 2026
Contracting authority
AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen
Procuring entityErfurt, Germany
Get the full picture
AI analysis, bid scoring, and expert strategy for this tender
Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.
See which competitors are winning the contracts you're chasing.
15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.